As expected, the USFDA has approved a product called Takhzyro made by a company called Shire for the treatment of a disease called HAE. The product should begin to have a commercial impact from the second half FY19.
The broker does not believe there will be a significant shift by patients to Takhzyro from CSL’s Haegarda but suggests there will be competition. Neutral and $220 target retained.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is $220.00.Current Price is $224.61. Difference: ($4.61) – (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately -2% (excluding dividends, fees and charges – negative figures indicate an expected loss).